NASDAQ:CCCC

C4 Therapeutics (CCCC) Stock Price, News & Analysis

C4 Therapeutics logo
$2.50 +0.06 (+2.25%)
Closing price 03:58 PM Eastern
Extended Trading
$2.46 -0.04 (-1.44%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About C4 Therapeutics Stock (NASDAQ:CCCC)

Advanced

Key Stats

Today's Range
$2.32
▼
$2.55
50-Day Range
$2.44
▼
$3.51
52-Week Range
$1.69
▼
$5.17
Volume
3.63 million shs
Average Volume
2.67 million shs
Market Capitalization
$327.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Moderate Buy

Company Overview

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. Founded in 2015, it develops medicines designed to selectively remove disease-causing proteins, with a focus on cancer.

The company uses its TORPEDO platform to design targeted protein degraders. These molecules are intended to bind a target protein and recruit the cell’s natural protein-disposal machinery, leading to the protein’s breakdown. C4 Therapeutics’ research and development programs include oral small-molecule candidates for oncology.

C4 Therapeutics is focused on drug discovery and clinical development and does not have marketed medicines. Its work is primarily based in the United States, with research and development collaborations extending its activities internationally.

AI Generated. May Contain Errors.

C4 Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

CCCC MarketRank™: 
2.132352941175 of 5 stars

C4 Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 599th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    C4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    C4 Therapeutics has a consensus price target of $8.50, representing about 240.7% upside from its current price of $2.50.

  • Amount of Analyst Coverage

    C4 Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about C4 Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for C4 Therapeutics are expected to decrease in the coming year, from ($0.73) to ($0.87) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of C4 Therapeutics is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of C4 Therapeutics is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    C4 Therapeutics has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    37.58% of the float of C4 Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    C4 Therapeutics has a short interest ratio ("days to cover") of 15.14, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in C4 Therapeutics has recently increased by 9.03%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    C4 Therapeutics does not currently pay a dividend.

  • Dividend Growth

    C4 Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    C4 Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for C4 Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 4 people have searched for CCCC on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, C4 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $122,419.00 in company stock.

  • Percentage Held by Insiders

    5.60% of the stock of C4 Therapeutics is held by insiders.

  • Percentage Held by Institutions

    78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about C4 Therapeutics' insider trading history.
Receive CCCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CCCC Stock News Headlines

C4 Therapeutics (CCCC) Stock Forecast & Price Target
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
FY2026 EPS Forecast for C4 Therapeutics Boosted by Analyst
FY2029 EPS Forecast for C4 Therapeutics Lowered by Analyst
See More Headlines

CCCC Stock Analysis - Frequently Asked Questions

C4 Therapeutics' stock was trading at $1.91 at the beginning of 2026. Since then, CCCC shares have increased by 30.6% and is now trading at $2.4950.

C4 Therapeutics, Inc. (NASDAQ:CCCC) posted its quarterly earnings results on Thursday, November, 5th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.03. The company had revenue of $8.47 million for the quarter, compared to the consensus estimate of $8.52 million. C4 Therapeutics had a negative net margin of 282.22% and a negative trailing twelve-month return on equity of 37.71%.

C4 Therapeutics (CCCC) raised $163 million in an initial public offering on Friday, October 2nd 2020. The company issued 9,600,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

Top institutional shareholders of C4 Therapeutics include RA Capital Management L.P. (6.24%), Goldman Sachs Group Inc. (3.57%), Soleus Capital Management L.P. (2.56%) and Candriam S.C.A. (2.24%). Insiders that own company stock include Kendra Adams, Leonard Reyno and Scott N Boyle.
View institutional ownership trends
.

Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that C4 Therapeutics investors own include MARA (MARA), Tesla (TSLA), IonQ (IONQ), Joby Aviation (JOBY), NVIDIA (NVDA), Palantir Technologies (PLTR) and SoundHound AI (SOUN).

Company Calendar

Last Earnings
11/05/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CCCC
CIK
1662579
Fax
N/A
Employees
104
Year Founded
2015

Price Target and Rating

High Price Target
$11.00
Low Price Target
$6.00
Potential Upside/Downside
+240.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$104.99 million
Net Margins
-282.22%
Pretax Margin
-281.85%
Return on Equity
-37.71%
Return on Assets
-26.42%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.17
Quick Ratio
5.17

Sales & Book Value

Annual Sales
$35.95 million
Price / Sales
9.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.74 per share
Price / Book
1.43

Miscellaneous

Outstanding Shares
131,320,000
Free Float
123,963,000
Market Cap
$327.64 million
Optionable
Optionable
Beta
3.16

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:CCCC) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners